Study to Monitor Subcutaneous Human Immunoglobulin Administered at Modified Dosing Regimens in Patients With Primary Immunodeficiency Diseases

Primary Immune Deficiency Disorder Clinical Trial

Official title:

Clinical Phase 3 Study to Monitor the Safety, Tolerability, and Efficacy of Subcutaneous Human Immunoglobulin (CUTAQUIG®) Administered at Modified Dosing Regimens in Patients With Primary Immunodeficiency Diseases

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03939533
• Other study ID #: SCGAM-06
• Status: Completed
• Phase: Phase 3
• Start date: October 17, 2019
• Est. completion date: January 3, 2022

Study information

• Verified date: November 2023
• Source: Octapharma
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

CLINICAL PHASE 3 STUDY TO MONITOR THE SAFETY, TOLERABILITY, AND EFFICACY OF SUBCUTANEOUS HUMAN IMMUNOGLOBULIN (CUTAQUIG®) ADMINISTERED AT MODIFIED DOSING REGIMENS IN PATIENTS WITH PRIMARY IMMUNODEFICIENCY DISEASES

Recruitment information / eligibility

• Status: Completed
• Enrollment: 64
• Est. completion date: January 3, 2022
• Est. primary completion date: January 3, 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 2 Years to 75 Years

Eligibility

Inclusion Criteria:

1. Age =2 years and =75 years.

2. Confirmed diagnosis of primary immunodeficiency (PI) disease as defined by the European Society for Immunodeficiencies and Pan American Group for Immunodeficiency and requiring immunoglobulin replacement therapy due to hypogammaglobulinaemia or agammaglobulinaemia. Note: The exact type of PI disease will be recorded.

3. Established on a consistent or stable mg/kg dose of any SCIG treatment for a minimum of 3 months prior to Screening. Note: patients entering Cohort 3 must be on weekly SCIG infusions for a minimum of 12 weeks.

4. Availability of the Immunoglobulin G (IgG) trough levels of 2 previous SCIG infusions within 1 year of Screening, with 1 trough level obtained within 3 months prior to enrollment, and maintenance of trough serum IgG levels =5.0 g/L in 2 previous infusions. Patients with no prior IgG trough level within 3 months prior to enrollment may use the Screening IgG trough level as their 2nd reading.

5. Voluntarily given, fully informed signed informed consent. For patients under the legal age of consent, voluntarily given, fully-informed, signed informed consent will be provided by patient's parent or legal guardian, and assent will be provided by patient (per age-appropriate Institutional Review Board [IRB] requirements).

6. Females of childbearing potential, who are not nursing and have no plans for pregnancy during the course of the study, have been using at least 1 acceptable form of birth control for a minimum of 30 days prior to the Screening visit and must agree to use at least 1 acceptable method of contraception for 30 days after the last dose of CUTAQUIG. Acceptable methods include: intrauterine device (IUD), hormonal contraception, male or female condom, spermicide gel, diaphragm, sponge, cervical cap, or abstinence.

7. For female patients of child-bearing potential, a negative result in a urine pregnancy test conducted at the Screening visit.

8. Willingness to comply with all aspects of the protocol, including blood sampling, for the duration of the study.

Exclusion Criteria:

1. Evidence of active infection within 4 weeks of Screening or during the Screening Period.

2. Current or clinically-significant history of any cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, neurological, immunological (excluding PI), hematologic, and/or psychiatric disorder(s), or a history of any other illness that, in the opinion of the Investigator, might confound the results of the study, or pose additional risk to the patient by participation in the study.

3. Known history of adverse reactions to immunoglobulin A (IgA) in other products.

4. Body mass index (BMI) >40 kg/m2 for patients entering Cohort 2 or Cohort 3. There are no BMI restrictions for Cohort 1.

5. Ongoing history of hypersensitivity or persistent reactions to blood or plasma derived products, or any component of the investigational product (such as Polysorbate 80).

6. Requirement of any routine premedication for IgG administration.

7. History of malignancies of lymphoid cells and immunodeficiency with lymphoma.

8. Severe liver function impairment (aspartate aminotransferase [AST] or alanine aminotransferase [ALT] >3 times above upper limit of normal).

9. Known protein-losing enteropathies or clinically significant proteinuria.

10. Presence of renal function impairment (creatine >120 µM/L or creatinine >1.35 mg/dL), or predisposition for acute renal failure (eg, any degree of preexisting renal insufficiency or routine treatment with known nephritic drugs).

11. Treatment with oral or parenteral steroids for =30 days, or when given intermittently or as bolus at daily doses =0.15 mg/kg when taken within 30 days of Screening. Note: Short or intermittent courses of steroids (ie, a steroid burst) of >0.15 mg/kg/day is allowed for treatment of a short-term condition such as an asthma exacerbation.

12. Treatment with immunosuppressive or immunomodulatory drugs (except Omalizumab).

13. Use of HYQVIA (Immune Globulin Infusion 10% [Human] with Recombinant Human Hyaluronidase) within 3 months prior to first CUTAQUIG infusion.

14. Live viral vaccination (such as measles, rubella, mumps, and varicella) within 2 months prior to first CUTAQUIG infusion.

15. Exposure to blood or any blood product or derivative, other than subcutaneous IgG used for regular PI disease treatment, within 3 months before the first CUTAQUIG infusion.

16. Treatment with any investigational medicinal product within 3 months prior to first CUTAQUIG infusion. Note: Patients participating in Study SCGAM-03 will be allowed to enter this study without the 3-month waiting period for an Investigational Product. Patients receiving another SCIG product within 3 months prior to the first CUTAQUIG infusion may be considered for enrollment after Sponsor approval.

17. Presence of any condition that is likely to interfere with the evaluation of CUTAQUIG or satisfactory conduct of the trial.

18. Known or suspected to abuse alcohol, drugs, psychotropic agents, or other chemicals within the past 12 months prior to first CUTAQUIG infusion.

19. Known active or chronic hepatitis B, hepatitis C, or HIV infection. Past hepatitis B or hepatitis C infection that has been cured is allowed.

Related Conditions & MeSH terms

• Immunologic Deficiency Syndromes
• Primary Immune Deficiency Disorder
• Primary Immunodeficiency Diseases

Intervention

Drug:
• CUTAQUIG
Human normal immunoglobulin

Locations

Country	Name	City	State
United States	Octapharma Research Site	Albany	Georgia
United States	Octapharma Research Site	Asheville	North Carolina
United States	Octapharma Research Site	Bellingham	Washington
United States	Octapharma Research Site	Centennial	Colorado
United States	Octapharma Research Site	Chevy Chase	Maryland
United States	Octapharma Research Site	Cincinnati	Ohio
United States	Octapharma Research Site	Dallas	Texas
United States	Octapharma Research Site	Irvine	California
United States	Octapharma Research Site	Louisville	Kentucky
United States	Octapharma Research Site	Mayfield	Ohio
United States	Octapharma Research Site	North Palm Beach	Florida
United States	Octapharma Research Site	Papillion	Nebraska
United States	Octapharma Research Site	Pittsburgh	Pennsylvania
United States	Octapharma Research Site	Saint Louis	Missouri
United States	Octapharma Research Site	Saint Petersburg	Florida
United States	Octapharma Research Site	Santa Barbara	California
United States	Octapharma Research Site	Scottsdale	Arizona
United States	Octapharma Research Site	Toledo	Ohio

Sponsors (1)

Lead Sponsor	Collaborator
Octapharma

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	IgG Trough Levels From Baseline to End of Study (28 Weeks)	Mean change from baseline in individual total IgG trough levels in cohort 3 from weekly infusions to end of study (28 weeks) every other week infusions, and for cohort 1 and cohort 2 (weekly infusions) change from baseline through study completion (28 weeks)	Through study completion, up to 28 weeks
Secondary	Serious Bacterial Infection Rates	Number of subjects who reported SBIs during the study	Through study completion, up to 28 weeks
Secondary	Time to Resolution of Infections	The amount of days it took for infectious disease occurrence and resolution for subjects	Through study completion, 28 weeks
Secondary	Antibiotic Usage	Amount of subjects treated with antibiotics during the study	Through study completion, up to 28 weeks
Secondary	Number of Antibiotic Treatment Episodes Annualized	Total number of treatment episodes annualized calculated as the sum of all unique episodes of antibiotics of all subjects from first dose day of cutaquig to last study visit/number of person years exposure	Through study completion, up to 28 weeks